Covista Inc. (CVSA) Company Overview

What does Covista do?

Covista Inc. is a New York Stock Exchange-listed healthcare education company operating under ticker CVSA. The company adopted the Covista name in February 2026 after decades as Adtalem Global Education, but the economic substance is unchanged: it owns five accredited institutions that educate nurses, physicians, veterinarians, counselors, educators, public-health professionals, and other working adults. Covista describes itself as the largest healthcare educator in the United States, a positioning supported by the breadth of its nursing, online graduate, medical, and veterinary programs rather than by a single campus or degree.

Five institutions, three reportable segments

The portfolio is organized into Chamberlain, Walden, and Medical and Veterinary. Chamberlain University concentrates on nursing and health professions. Walden University is a fully online institution serving working adults across nursing, education, counseling, psychology, business, information technology, public health, social work, and related disciplines. The third segment combines American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. Covista's official company story connects these institutions through a common purpose: expanding the healthcare workforce at scale.

Why Covista matters to healthcare capacity

Covista matters because its output is tied to healthcare labor shortages. Nursing programs, residency preparation, clinical rotations, and employer partnerships connect enrollment directly to workforce supply. The opportunity is attractive, but the burden of proof is high: outcomes, affordability, accreditation, and clinical access must remain credible. Covista is therefore best understood as a regulated human-capital platform, not simply a collection of online courses.

How does Covista make money, and which segment matters most?

Covista earns most of its revenue from tuition and education-related fees. Revenue is generally recognized over the academic term as instruction is delivered, while housing and other student services contribute a smaller amount. This model creates recurring cohorts rather than contractual subscription revenue: each term brings tuition from continuing students plus new starts, but retention, academic progression, and program completion determine how durable that revenue becomes. Federal student-aid programs are also integral to payment capacity, making regulation a direct input into revenue quality.

The revenue mix is balanced between nursing and online graduate education

Walden was slightly smaller than Chamberlain by fiscal 2025 revenue but generated the highest segment adjusted operating income: $183.6 million versus $153.4 million for Chamberlain and $69.3 million for Medical and Veterinary. Digital delivery can scale without replicating a campus for every learner. Chamberlain requires local facilities and clinical coordination, while Medical and Veterinary carries laboratories, island campuses, clinical rotations, and heavier professional-school regulation.

The audited fiscal 2025 Form 10-K supports these figures. The strategic tension is clear: Covista wants Walden-like digital scalability without weakening the clinical infrastructure that makes its credentials credible.

Which strategic turning points shaped Covista's current model?

Covista became a healthcare-focused educator through acquisition, divestiture, and concentration. Long-standing institutions contribute accreditation and alumni networks; acquisitions created scale; portfolio exits removed unrelated assets but left acquired intangibles and some legacy obligations.

From diversified education group to healthcare platform

1. 2003
   RUSM and RUSVM joined the portfolio. The transactions established Covista in medical and veterinary professional education and created exposure to Caribbean campus operations.
2. 2005
   Chamberlain was acquired. Nursing became the foundation for today's largest revenue segment and later expanded from a college into a broader university.
3. 2011
   AUC was acquired. A second medical school diversified professional-school enrollment and clinical-placement relationships.
4. 2018
   DeVry University was sold. The exit marked a decisive retreat from the legacy broad-based career-education identity, although certain litigation and indemnification exposure continued.
5. 2021
   Walden was acquired. The deal added a national online platform, graduate-degree scale, and debt that management subsequently worked to reduce and refinance.
6. 2022
   Financial-services education assets were divested. Selling ACAMS, Becker, OnCourse Learning, and EduPristine completed the move toward a healthcare-led portfolio.
7. 2026
   Adtalem became Covista and the ticker changed to CVSA. The rebrand aligned the corporate name with a single healthcare-workforce narrative rather than the former collection of education brands.

The official name-change announcement was a strategic milestone, not a legal reset. The institutions, debt, regulatory obligations, and financial history remain continuous; Covista is the latest stage of a long portfolio transformation.

What does Covista's latest quarter show?

The third quarter of fiscal 2026, ended March 31, 2026, combined enrollment growth with a material calendar effect. Total enrollment reached 100,585, up 6.8% and marking the eleventh consecutive growth quarter. Revenue was $487.0 million, up 4.5%; management estimated 8.4% growth after adjusting for a one-week Walden calendar shift that moved about $18.0 million into the prior quarter.

Growth crossed 100,000 students

Margin pressure was mix and timing, not a collapse in demand

For the nine months ended March 31, 2026, revenue was $1.453 billion and operating cash flow was $346.5 million. The latest Form 10-Q provides GAAP detail, while the official earnings release explains the timing shift and raised guidance. Management expects fiscal 2026 revenue of $1.930 billion to $1.945 billion and adjusted EPS of $7.95 to $8.15, indicating confidence that enrollment growth can offset near-term timing noise.

Why is Covista difficult to replicate?

Covista's moat is not a patent or a consumer network effect. It is a layered institutional system: accreditation, program approvals, faculty, clinical affiliates, employer relationships, student-support capabilities, marketing data, and alumni outcomes. A new entrant can launch online course content quickly, but it cannot instantly recreate the authority to award regulated degrees, secure thousands of clinical placements, or produce a long record of licensure and residency outcomes.

Scale, clinical infrastructure, and program breadth reinforce one another

Chamberlain's combination of campus-based pre-licensure education and national online programs allows Covista to serve students at different career stages. Walden adds a large online catalog and graduate-degree depth. The medical and veterinary schools add scarce professional credentials and clinical pathways. Together, these assets produce cross-portfolio marketing knowledge and shared technology investment, while each institution retains the specialized approvals its programs require.

Outcomes and employer integration reinforce the enrollment funnel

Outcomes are strategic assets. In the 2025–2026 residency cycle, AUC and RUSM reported 97% first-time residency attainment, with more than 750 graduates placed across over 400 healthcare facilities. Employer integration can deepen this advantage by connecting curriculum, clinical experience, and hiring while reducing reliance on broad consumer marketing.

The moat is conditional. Poor outcomes, aggressive recruiting, regulatory findings, clinical bottlenecks, or affordability concerns could weaken demand quickly. Covista must keep reinvesting in faculty, compliance, learner support, technology, and program relevance; scale is valuable only while institution-level outcomes justify it.

Who competes with Covista, and where is it vulnerable?

Covista faces different competitors by segment. Chamberlain competes with nursing schools, community colleges, and online programs; Walden with nonprofit, public online, and proprietary universities; AUC and RUSM with U.S. and international medical schools; and RUSVM with accredited veterinary programs. Subsidized public institutions can charge less, creating meaningful price pressure.

Competition changes by segment

A strategy-class view of market position

This matrix is an interpretation, not a company-reported market-share chart. Specialization raises barriers and relevance, while scale improves marketing and technology economics. The trade-off is stricter oversight: scale magnifies any compliance failure, poor outcome, or reputational event.

How strong are cash flow, debt, and capital allocation?

Fiscal 2025 revenue was $1.788 billion, operating income was $341.5 million, and net income was $237.1 million. Continuing operating cash flow of $333.7 million less $50.3 million of capital expenditure produced about $283.4 million of simple free cash flow. Covista is not heavily capital intensive at the consolidated level, although campuses and technology require targeted investment.

Cash conversion funds both growth and capital return

This cash generation can fund campuses, digital products, debt service, and repurchases. Free cash flow is not guaranteed to remain low-capex: new locations require upfront investment, and academic-term or federal-aid timing can make quarterly cash flow uneven.

Debt was simplified, but acquired intangibles remain important

In March 2026, Covista refinanced its prior term loan and senior notes into a $510 million Term Loan B due 2033. The longer maturity reduces near-term refinancing pressure, while 0.7 times net leverage indicates substantial earnings coverage. However, the balance sheet still reflects the acquisition strategy: goodwill and intangible assets totaled roughly $1.72 billion at March 31, 2026. Those assets are not cash obligations, but they make future impairment testing sensitive to enrollment, margins, discount rates, and long-term growth assumptions.

Capital allocation balances growth, debt discipline, and buybacks. In fiscal 2025, Covista repurchased about 2.32 million shares at an average $91.21 and prepaid $100 million of term debt. Its official annual reports page shows a preference for reinvestment, deleveraging, and per-share value creation rather than a regular dividend model.

Who owns Covista stock, and how is it governed?

Covista has one common share class and no founder-controlled dual-class structure, so economic ownership and voting influence are aligned. BlackRock, Vanguard, and Dimensional Fund Advisors were the largest owners disclosed in the 2025 proxy. None controls the company, but large asset managers have meaningful influence over directors, compensation, and governance.

Dispersed institutional control

Incentives emphasize revenue and adjusted EPS

Steve Beard serves as chairman and chief executive officer, while a lead independent director provides counterbalance. The board maintained five standing committees in fiscal 2025, and the Audit and Finance, Compensation, and Nominating and Governance committees were fully independent. The annual incentive plan used revenue and adjusted EPS as core financial measures, which aligns management with growth and per-share earnings but can also encourage investors to scrutinize adjustments, repurchases, and the quality of enrollment growth.

The 2025 definitive proxy statement is the authoritative source. Strategy remains contestable through ordinary governance channels: institutional owners can press for change without overcoming a controlling shareholder.

Purpose at Scale: opportunities and risks through fiscal 2029

Covista's “Purpose at Scale” plan extends the current model through employer integration, operational excellence, technology, and platform expansion. Management targets more than 120,000 students by fiscal 2029, revenue compound growth of 7% to 10% from the fiscal 2026 guidance midpoint, and adjusted EPS compound growth of 10% to 14%. The plan requires both enrollment expansion and operating leverage.

Where management expects growth

The 2026 Investor Day presentation describes a typical new Chamberlain campus as requiring about $9 million to $12 million of capital, reaching 450 to 500 students, becoming EBITDA-positive within 24 months, and eventually exceeding a 30% EBITDA margin. The economics are attractive only if approvals and enrollment ramps match the model.

What could break the model?

The most company-specific risk is federal student-aid access. Covista's institutions have operated under provisional certification and heightened cash monitoring after a weak fiscal 2022 financial-responsibility score tied to the Walden acquisition and other transactions. Management does not expect a material adverse effect, but the issue links leverage, acquired intangibles, and regulatory liquidity requirements.

What matters most in a DCF and what should researchers monitor?

A Covista valuation should begin with enrollment cohorts. Revenue reflects starts, retention, mix, tuition, and calendar timing; margin reflects marketing, clinical costs, campus utilization, and digital scale; cash flow then depends on capex, aid timing, debt service, and repurchases.

Value drivers

The integrated takeaway